HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: Carlyle Backs Pharma Venture, Nutranomics CEO Returns

This article was originally published in The Tan Sheet

Executive Summary

NSF adds 'next generation' DNA ID service; Dietary Guidelines updated; NPA in anti-internet tax coalition; GNC hires financial communications firm; and more news in brief.

You may also be interested in...



Industry Groups Suggest 'Healthy Eating' Approach On Label Enforcement

Supplement industry trade associations urge FDA to consider expanding the scope of products eligible to use “healthy” on product labels, though NPA says the issue could be on the backburner for the Trump administration.

EU Health Ministers Want Changes to COVID-19 Vaccine Contracts Amid Oversupply Concerns

EU member states are calling for a formal approach to making vaccine procurement agreements more flexible, saying that any further delay will “undermine the trust of society in vaccination and vaccines.”

Direction of Travel Of EU HTA Regulation Is ‘Disappointing’ For Advanced Therapies

Without further work, the EU-wide joint clinical assessments introduced by the EU regulation on health technology assessments will fail to meet the needs of advanced therapies, warns the Alliance for Regenerative Medicine.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS108764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel